Authors

Latest:

Dr. Camidge on Biomarker Combinations in NSCLC

David Ross Camidge, MD, PhD, professor, Division of Medical Oncology, Joyce Zeff Chair in Lung Cancer Research, School of Medicine, Division of Medical Oncology, University of Colorado, discusses biomarker combinations in non–small cell lung cancer (NSCLC).

David S. Hong, MD

David S Hong, MD is Deputy Chair of the Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.

Latest:

Dr Hong on the FDA Approval of Larotrectinib for NTRK+ Solid Tumors

David S. Hong, MD, discusses the FDA’s full approval of larotrectinib for patients with solid tumors harboring an NTRK gene fusion.

David S. Hong, MD, MD Anderson Cancer Center

David S. Siegel, MD, PhD

David S. Siegel, MD, is the chief of the Division of Multiple Myeloma at the John Theurer Cancer Center at Hackensack University Medical Center in New Jersey.

Latest:

Dr Siegel on the Evaluation of Mezigdomide for R/R Myeloma

David S. Siegel, MD, explains the rationale for assessing mezigdomide—a novel thalidomide derivative—in relapsed/refractory multiple myeloma.

David S. Snyder, MD

Latest:

Dr. Snyder on How Ruxolitinib and Fedratinib May Pave the Way to Transplant in Myelofibrosis

David S. Snyder, MD, discusses how ruxolitinib and fedratinib may be used to pave the way toward transplant for patients with myelofibrosis.

David S. Snyder, MD, FACP, City of Hope

David Sallman, MD

Latest:

Dr Sallman on the Significance of the FDA Approval of Frontline Luspatercept for Lower-Risk MDS

David Sallman, MD, discusses the clinical implications of the 2023 FDA approval of luspatercept for patients with very low– to intermediate-risk MDS.

David Schenkein, MD

Latest:

Dr. Schenkein on AG-221 for the Treatment of AML

David Schenkein, MD, Chief Executive Officer, Agios Pharmaceuticals, discusses AG-221 for the treatment of acute myeloid leukemia (AML).

David Sher, MD

Latest:

Dr Sher on the Efficacy and Safety of Daily Adaptive Radiotherapy in HNSCC

David Sher, MD, discusses efficacy outcomes with daily adaptive radiotherapy with 1-mm planning target volume margins in patients with head and neck squamous cell carcinoma.

David Spigel, MD

Latest:

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

Experts from across oncology specialties discuss the abstracts and presentations they are most looking forward to seeing at the 2024 ESMO Congress.

David Spigel, MD, Sarah Cannon Research Institute

David T. Marshall, MD

Latest:

Dr. Marshall on ASCENDE-RT Trial for Prostate Cancer

David T. Marshall, MD, MS, professor, director, Medical Residency Program, Department of Radiation Oncology, Medical University of South Carolina, discusses the ASCENDE-RT trial, which compared dose-escalated external beam radiation therapy versus low-dose-rate brachytherapy for men with unfavorable-risk localized prostate cancer.

David Tom Cooke, MD, FCCP, FACS

Latest:

MEDCAC Ruling on Lung Cancer Screening

The MEDCAC ruling will likely lead to non-coverage of lung cancer screening with low dose CT scans for Medicare and Medicaid beneficiaries.

David Vesole, MD, PhD

Latest:

Inside the Clinic: JTCC Experts Highlight Key Takeaways from ASH 2021

David Siegel, MD, PhD, Noa Biran, MD, and David H. Vesole, MD, PhD, discuss key takeaways from ASH 2021.

David Wheeler, CPA, MBA

Latest:

Dipping a Toe Into Care Management

Fee-for-service remains the primary driver of patient revenue for the majority of oncology practices across the country, and the same is true for The Center for Cancer and Blood Disorders.

Dawn Dolan, PharmD, BCOP, Moffitt Cancer Center

Dawn Hershman, MD, MS

Latest:

Dr. Hershman on the Use of Endocrine Therapy in Premenopausal HR+/HER2- Breast Cancer

Dawn Hershman, MD, MS, professor of medicine and epidemiology, leader of the Breast Cancer Program of the Herbert Irving Comprehensive Cancer Center at Columbia University, discusses the use of endocrine therapy in premenopausal women with early-stage hormone receptor (HR)–positive, HER2-negative breast cancer.

Dawn L. Hershman, MD

Latest:

Dr. Hershman on Late Effects of Intermittent ADT for Prostate Cancer Patients

Dawn Hershman, MD, Associate Professor Medicine at Columbia University Medical Center, discusses the late-effects of intermittent androgen deprivation therapy (ADT) to continuous ADT in prostate cancer.

Dawn L. Hershman, MD, MS

Latest:

Dr. Hershman on Misconceptions With the TAILORx Trial in HR+/HER2- Breast Cancer

Dawn L. Hershman, MD, MS, discusses the design of the phase III TAILORx trial in hormone receptor (HR)–positive, HER2-negative breast cancer.

Dean F. Bajorin, MD, Memorial Sloan Kettering Cancer Center